T-Cure Bioscience Announces US FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T against Multiple Solid Tumors

T–Cure Bioscience, Inc. announced that the US FDA has approved the Investigational New Drug application to initiate a Phase I clinical study evaluating a T cell receptor (TCR)–based product candidate for the treatment of tumors expressing Kita–Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervical, lung, breast cancers and other KK–LC–1 positive epithelial cancers.